Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Relypsa, Inc.
Approximately 110 eligible participants with hyperkalemia will be randomly assigned to receive a patiromer starting dose of 8.4- g/day, either with or without food.
All participants will undergo a screening period (1 day) to determine eligibility for study entry. Eligible participants will be treated for 4 weeks and followed for 2 weeks after completing the patiromer treatment. There are six planned clinic visits during the Treatment Period and two planned visits after the last dose of patiromer during the Follow-up Period.
The dose of patiromer may be increased or decreased (titrated) based on participants' individual potassium response.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Potassium concentration \> 5.0 mEq/L from two blood draws at Screening
Stable RAASi medication, if taking
Medications taken on a chronic basis are given once daily or twice daily
Informed consent given
You may not be if
Expected need for dialysis
Major organ transplant
History of conditions associated with pseudohyperkalemia
History of swallowing disorder, gastroparesis, bariatric surgery, bowel obstruction or severe gastrointestinal disorders or major gastrointestinal surgery
Cancer or unstable medical condition
Clareo Health | Patiromer With or Without Food for the Treatment of Hyperkalemia